The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
After Phase 3 results show major hair regrowth gains
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
Subscribe To Our Newsletter & Stay Updated
